Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological

Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet

Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial - The Lancet

2-Hydroxypropyl-β-cyclodextrin Ototoxicity in Adult Rats: Rapid Onset and Massive Destruction of Both Inner and Outer Hair Cells Above a Critical Dose

Frontiers The Effects of Combined Therapy With Metformin and Hydroxypropyl -β-Cyclodextrin in a Mouse Model of Niemann-Pick Disease Type C1

Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from Monocytes: Possible Implications for Suppression of HIV Chronic Immune Activation

Frontiers Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment

Frontiers Pro-Inflammatory Implications of 2-Hydroxypropyl-β-cyclodextrin Treatment

Biomolecules, Free Full-Text

Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann–Pick C1 mutant cell via lysosome-associated membrane protein 1

Repeated Administration of 2-Hydroxypropyl-β-Cyclodextrin (HPβCD) Attenuates the Chronic Inflammatory Response to Experimental Stroke

Biomolecules, Free Full-Text